Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 May 19;192(20):E552.
doi: 10.1503/cmaj.191165.

Sunitinib-induced pyoderma gangrenosum-like skin ulcer

Thomas Kuntz  1 , Bijan Koushk-Jalali  1 , Alexander Kreuter  2
Affiliations
Case Reports

Sunitinib-induced pyoderma gangrenosum-like skin ulcer

Thomas Kuntz et al. CMAJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1:
Figure 1:
A superficial ulcer (50–80 mm in diameter) on the right medial malleolus of an 80-year-old woman with renal cell carcinoma who was taking sunitinib. Cutaneous signs of chronic venous insufficiency (corona phlebectatica and mild ankle edema) were present; however, no abnormal blood flow was found on examination using colour ultrasonography.
See this image and copyright information in PMC

References

    1. Lopez Pineiro M, Willis E, Yao C, et al. Pyoderma gangrenosum-like ulceration of the lower extremity secondary to sunitinib therapy: a case report. SAGE Open Med Case Rep 2018; 6: 2050313X18783048. - PMC - PubMed
    1. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009;161:1045–51. - PubMed
    1. Puig L. Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. Curr Probl Dermatol 2018;53:49–63. - PubMed

Publication types

MeSH terms